|   Welcome to the M&M Lab.

Led by Mala Shanmugam, we study the role of Metabolism in Myeloma.


Mala Shanmugam, PhD
Mala Shanmugam, PhD, MS, is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University, School of Medicine. Dr. Shanmugam is a member of the Cancer Cell Biology Research Program and the Molecular and Systems Pharmacology at GDBBS Emory.

Dr. Shanmugam attended Madurai Kamaraj University in T. Nadu, India where she earned a MS in Biotechnology. She received her PhD in Tumor Cell Biology from Northwestern University Medical School in Chicago, IL. She completed her fellowship training at Northwestern University Medical School and at Loyola University of Chicago Medical Center.
Richa Bajpai, PhD
Associate Scientist
Institute of Microbial Technology, Jawaharlal Nehru University (PhD, Molecular Biology)
CSJM University (MS, Biotechnology)
Lucknow University (BS, Botany/Chemistry)

Research Focus:
Multiple Myeloma, Apoptosis, BCL-2 proteins, Metabolism

Aditi Sharma, PhD
Postdoctoral Scholar
Georgia Tech (MS+PhD, Bioengineering)
IIT Delhi (BS+MT, Biochemical Engineering and Biotechnology)

Research Focus:
Lung Adenocarcinoma, Collective Cell Invasion, Metabolism

Arusha Siddiqa, BS
Research Specialist
Georgia Tech (BS, Biomedical Engineering)

Research Focus:
Multiple Myeloma, Apoptosis, BCL-2 proteins, Metabolism

Kimberly Amelsberg
Summer Intern
Emory (Rising junior, Chemistry and Biology)

Ethan Wedge
Emory Scholar Intern
Choate High School (Rising senior)



The central interest of our lab is to understand how metabolism regulates cellular function with the objective of identifying metabolic vulnerabilities that can be targeted to regulate specific biology. In this context we investigate therapy resistance and the BCL-2 family of proteins in multiple myeloma and the metabolic basis of invasion/metastasis in lung adenocarcinoma.

We use metabolite profiling, metabolite flux and cellular bioenergetics assays and examine signaling in the context of biochemical, cellular and molecular interventions to investigate these questions in cell line, patient sample and in vivo models. Our long-term goals are thus:

  • To better understand the functional implications of altered cellular metabolism in cancer
  • To elucidate how nutrient metabolism signals to promote cancer cell survival and metastasis
  • To investigate cancer metabolism as a conduit to understanding therapy resistance that can be perturbed to orchestrate potent strategies of synthetic lethality with existing therapy
We're actively recruiting graduate students this year so feel free to contact us at the email below!


Evaluating the Efficacy of GLUT Inhibitors Using a Seahorse Extracellular Flux Analyzer.
Wei C, Heitmeier M, Hruz PW, Shanmugam M.
Methods in Molecular Biology, 2018

Development of GLUT4-selective antagonists for multiple myeloma therapy
Changyong Wei, Richa Bajpai, Horrick Sharma, Monique Heitmeier, Atul D. Jain, Shannon M. Matulis, Ajay K. Nooka, Rama K. Mishra, Paul W. Hruz, Gary E. Schiltz, Mala Shanmugam
European Journal of Medicinal Chemistry, 2017

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to ABT-199
Richa Bajpai, Shannon M Matulis, Changyong Wei, Ajay K Nooka, Hayley E Von Holen, Sagar Lonial, Lawrence H Boise and Mala Shanmugam
Oncogene, 2016

In Silico Modeling-based Identification of GLUT4 Selective Inhibitors for Cancer Therapy
Mishra RK, Wei C, Hresko RC, Bajpai R, Heitmeier M, Matulis SM, Nooka AK, Rosen ST, Hruz PW, Schiltz GE, Shanmugam M.
Journal of Biological Chemistry, 2015

See more